TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
RGNX

Regenxbio Inc

Healthcare · Biotechnology

7.40$ +2.2% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow RGNX
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-39.2% -296.7% -1,058.1% -558.0% 47.9% -305.7% -35.0% 46.5% -184.1% -242.0% -207.8% -72.7%
1.3% 1.1% 11.9% 25.8% 1.8% 20.3% 5.4% 2.0% 11.5% 19.2% 19.5% 9.2%
5.2% 38.5% 153.2% 102.0% 7.6% 76.2% 20.7% 8.3% 36.2% 44.6% 46.2% 20.3%
8.1% 42.9% 188.2% 111.6% 7.6% 60.0% 26.2% 8.8% 40.8% – – –
18.1% -40.1% 113.9% 8.6% -3.6% -15.1% 9.2% 8.6% 12.4% -12.1% 6.6% 6.9%
8.5% 6.9% 177.6% 68.9% 6.1% 33.3% 17.4% 17.9% 27.3% 11.0% 2.9% 1.4%
-2,676.5% -2,158.7% 417.6% -46.1% -127.8% 265.5% 79.4% -86.5% -10.6% 211.6% 124.1% -9.3%
– 0.0% 0.0% 0.0% – – – – – – – –
0.0% 3,153.8% 3.9% 5.3% 0.4% 3.7% 1.2% 0.0% -0.3% -0.5% 1.4% 0.6%
39.2% – – – – – – – – – 0.0% 84.8%
39.2% 3,153.8% 2.6% 814.0% 93.6% 23.8% 129.5% 41.5% -25.6% -38.7% 111.2% 68.5%
0.0% 698.4% -638.0% 209.9% 13.6% -16.4% 174.0% 1.6% -220.2% -69.2% 27.6% -13.5%
-39.2% -303.6% -1,235.7% -626.9% 41.8% -339.0% -52.4% 28.6% -211.3% -253.1% -210.7% -74.1%

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?